Loading...
The dual pathway inhibitor rigosertib is effective in direct-patient tumor xenografts of head and neck squamous cell carcinomas
The dual pathway inhibitor rigosertib inhibits phosphoinositide 3-kinase (PI3K) pathway activation as well as polo-like kinase 1 (PLK1) activity across a broad spectrum of cancer cell lines. The importance of PIK3CA alterations in head and neck squamous cell cancer (HNSCC) has raised interest in exp...
Na minha lista:
Main Authors: | , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Artigo |
Sprog: | Inglês |
Udgivet: |
2013
|
Fag: | |
Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3796006/ https://ncbi.nlm.nih.gov/pubmed/23873848 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-13-0206 |
Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|